Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Global X Cybersecurity (BUG) vs Cassava Sciences Inc (FLNA) Price & Performance

Global X CybersecurityTrade
Cassava Sciences IncTrade

Price performance (Past 24H)

Key statistics

Global X Cybersecurity vs Cassava Sciences Inc — how do they compare? Global X Cybersecurity trades at $42.93, while Cassava Sciences Inc trades at $0.97 (market cap $47.75M). The key difference: Global X Cybersecurity is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.

BUGFLNA
Sector
Sector/ThematicHealth
52-Week High
$43.00$4.64
52-Week Low
$23.30$0.87
Market Cap
$47.75M
Enterprise Value
-$34.93M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Global X Cybersecurity

BUG, the Global X Cybersecurity ETF, trades at $41.68, up 2.36% today and near its 52-week high, with a strong bullish technical signal from moving averages. The ETF has gained significant momentum, rising 82.25% from its 52-week low, as cybersecurity spending forecasts exceed $300 billion in 2026. Recent news highlights sector resilience against AI threats, though key financial ratios like P/E and P/S are not provided in the available data.

The outlook for BUG is positive, driven by robust cybersecurity demand and AI-related security needs, but risks include premium valuations, concentrated US SMID-cap exposure, and potential sector volatility. Analyst sentiment remains bullish with reiterated buy ratings, yet investors should note overbought short-term signals and competitive pressures in the evolving tech landscape.

Cassava Sciences Inc

FLNA trades at $0.995, up 3.75% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of -$0.18 beating expectations of -$0.225. Financials show negative cash flows and profitability, with ROE at -55.79% and net income of -$90.97M in 2025. Analyst consensus is strongly positive with 8 buy ratings out of 12.

Despite operational losses, FLNA's consistent earnings beats and strong analyst support suggest potential upside if clinical developments progress. Key risks include sustained cash burn, lack of revenue, and dependence on successful drug trials for Tuberous Sclerosis Complex. The stock remains speculative with high volatility expected.

Returns comparison

Trailing returns across standard periods

About Global X Cybersecurity

BUG is a thematic ETF that invests in companies at the forefront of the global cybersecurity industry. It provides concentrated exposure to leaders in network security, endpoint protection, and cloud security, such as Fortinet, Akamai, and CrowdStrike.

Read more on BUG

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA